iRadimed (NASDAQ:IRMD) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

02 May 2026, 14:14 by Doug Wharley · The Cerbat Gem

iRadimed (NASDAQ:IRMD – Get Free Report) announced its quarterly earnings results on Friday. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03, FiscalAI reports. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The company had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed updated its FY 2026 guidance to 2.060-2.210 EPS and its Q2 2026 guidance to 0.440-0.480 EPS.

Here are the key takeaways from iRadimed’s conference call:

Record quarter and raised guidance: Q2 revenue was $20.4M (+14% YoY) with 78% gross margin and GAAP diluted EPS of $0.45 (+18% YoY); management raised FY2025 revenue guidance to $80.0–$82.5M, raised EPS ranges, and declared a $0.17 quarterly dividend.
FDA clearance of the MRidium 3870: Management calls the clearance a “seminal” event and expects the new pump (≈12% higher ASP) to unlock large replacement demand from >6,200 U.S. 5+-year-old channels, targeting an eventual domestic pump device revenue lift toward ~$50M in 2026.
Backlog and commercial cadence: The company reports a record backlog (pump backlog ~5–6 months, monitor backlog ~4–5 weeks) and plans a controlled rollout—limiting broad selling of the 3870 through year‑end—so pump bookings may be muted initially even while revenue is supported by backlog.
Near-term headwinds and international softness: International revenue declined 9% (domestic now ~89% of sales), the facility move will cause short-lived operational inefficiencies, and ongoing capex (final facility payments) could pressure near-term free cash flow and operating expenses.

iRadimed Price Performance

NASDAQ:IRMD traded up $3.71 during mid-day trading on Friday, hitting $87.15. 346,336 shares of the company’s stock were exchanged, compared to its average volume of 103,465. iRadimed has a one year low of $50.31 and a one year high of $107.90. The business has a fifty day moving average price of $96.69 and a 200 day moving average price of $93.87. The company has a market cap of $1.11 billion, a PE ratio of 49.80 and a beta of 1.11.

iRadimed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is presently 45.71%.

Analysts Set New Price Targets

IRMD has been the topic of several research analyst reports. Lake Street Capital reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, iRadimed presently has a consensus rating of “Buy” and a consensus price target of $120.00.

View Our Latest Stock Analysis on iRadimed

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 3,750 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $89.16, for a total transaction of $334,350.00. Following the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at $196,040,550. The trade was a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 48,750 shares of company stock worth $4,708,950 over the last 90 days. Insiders own 36.80% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Several hedge funds have recently bought and sold shares of IRMD. Quarry LP bought a new stake in iRadimed during the third quarter worth about $40,000. Tower Research Capital LLC TRC boosted its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares in the last quarter. Virtus Advisers LLC bought a new stake in iRadimed during the third quarter worth about $117,000. Aquatic Capital Management LLC boosted its stake in iRadimed by 210,400.0% during the third quarter. Aquatic Capital Management LLC now owns 2,105 shares of the medical equipment provider’s stock worth $150,000 after acquiring an additional 2,104 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in iRadimed during the third quarter worth about $164,000. Institutional investors own 92.34% of the company’s stock.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

About iRadimed

(Get Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.